GSK now expects 20+ phase III trial starts in 2026, up from 10

GSK•2026-07-28

Q2 2026 performance

The updated expectations follow Q2 2026 performance with total sales of £8.4 billion, up 5%, and core operating profit of £2.8 billion, up 7%.

Cost-savings program

Management flagged a 3-year cost-savings program to fund late-stage portfolio investment, with some savings aimed at supporting margins in 2028-2030.

Updated 2026 R&D outlook

GSK now expects more than 20 Phase III trial starts in 2026, up from 10 previously.

Sources

GSK now expects 20+ phase III trial starts in 2026, up from 10

Docs

GSK now expects 20+ phase III trial starts in 2026, up from 10

Q2 2026 performance

Cost-savings program

Updated 2026 R&D outlook

Related News

Textron tops quarterly results estimates on higher aircraft pricing

Loyal Solutions powers Visa Germany’s Visa Bonus cash-back program

Covista Names Emily C. Chiu And Leslie Storms To Its Board Of Directors

Sources

GSK now expects 20+ phase III trial starts in 2026, up from 10

Standard BioTools to sell mass cytometry business to Multiplex Bio for up to $10 million

Paccar Q2 Revenue USD 7,550 Million Vs. IBES Estimate USD 7,264 Million